CD274 and neoplasm: Blocking the PD-1/PD-L1 pathway with anti-PD-1 or anti-PD-L1 antibodies has demonstrated promising therapeutic efficacy in a variety of tumor types (32–35); however, response rates are only 10%–30% (29, 36).